Valeant Says 9th Circ.'s FCA Disclosure Ruling Went Too Far
The drugmaker behind a major bowel disease treatment said that a Ninth Circuit panel split with "at least eleven" other appeals courts when it ruled that putting together disclosures from patent...To view the full article, register now.
Already a subscriber? Click here to view full article